Beneficial effects of raloxifene and atorvastatin on serum lipids and HDL phospholipids levels of postmenopausal women

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Obstetrics and Gynaecology Research

• Publication date

  2004-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/01443610410001685565PMID 15203583
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Selective estrogen-receptor modulators.

  2003cited by this paper
• Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients DOI 10.1194/jlr.M200037-JLR200

  2002influential reference
• Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients.

  2002influential reference
• Efficacy of Raloxifene for Treatment of Menopause: A Systematic Review

  2002cited by this paper
• Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk.

  2002influential reference
• Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators.

  2001cited by this paper
• Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia.

  2001cited by this paper
• Effect of atorvastatin on serum uric acid levels.

  2001cited by this paper
• Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia.

  2001influential reference
• Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively.

  2001influential reference
• Effect of Atorvastatin on Serum Creatinine Levels

  2001cited by this paper
• Comparison of efficacy and safety of atorvastatin (10 mg) with simvastatin (10 mg) at six weeks

  2001cited by this paper
• Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients.

  2000cited by this paper
• Résultats des études cliniques internationales du raloxifène

  1999cited by this paper
• The Impact of Estrogen Replacement Therapy and Raloxifene on Osteoporosis, Cardiovascular Disease, and Gynecologic Cancers

  1999cited by this paper
• [Results of international clinical trials with raloxifene].

  1999cited by this paper
• Effects of hormone replacement therapy on serum lipids and phospholipids in postmenopausal women.

  1999cited by this paper
• Raloxifene: designer estrogen for preventing postmenopausal osteoporosis.

  1999cited by this paper
• Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.

  1998cited by this paper
• Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.

  1998cited by this paper
• Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

  1998cited by this paper
• Selective Estrogen Receptor Modulators: An Alternative to Hormone Replacement Therapy

  1998cited by this paper
• Treatment of Established Postmenopausal Osteoporosis with Raloxifene: A Randomized Trial

  1998cited by this paper
• Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

  1998cited by this paper
• Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). 1998.

  1997cited by this paper
• Identification of an Estrogen Response Element Activated by Metabolites of 17β-Estradiol and Raloxifene

  1996cited by this paper
• Menopause and risk of cardiovascular disease.

  1996cited by this paper
• A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women

  1996cited by this paper
• The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

  1996cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

  1995cited by this paper
• Menopause and the risk of coronary heart disease in women.

  1987cited by this paper
• Menopause and the risk of coronary heart disease in women.

  1987cited by this paper
• Determination of high-density lipoprotein phospholipids in serum.

  1980cited by this paper
• Menopause and risk of cardiovascular disease: the Framingham study.

  1977cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper

• Dysfunctional High-Density Lipoproteins: Role in Atherogenesis and Potential Targets for Phospholipid Therapy

  2018cites this paper
• Sphingomyelin in High-Density Lipoproteins: Structural Role and Biological Function

  2013cites this paper
• Effect of Raloxifene on Serum Lipids for Type 2 Diabetic Menopausal Women with or without Statin Treatment

  2009cites this paper
• Factors Associated with Findings of Published Trials of Drug–Drug Comparisons: Why Some Statins Appear More Efficacious than Others

  2007cites this paper
• Methode de diminution des risques d'episodes cardio-vasculaires dommageables associes a l'administration d'agents pharmaceutiques favorisant ce type d'episodes

  2006cites this paper
• Absorption and lipoprotein transport of sphingomyelin Published, JLR Papers in Press, October 26, 2005.

  2006cites this paper
• Raloxifene: A Selective Estrogen-Receptor Modulator for Postmenopausal Osteoporosis – a Clinical Update on Efficacy and Safety

  2006cites this paper
• Verfahren zur verringerung des risikos von unerwünschten kardivaskulären (cv) ereignissen in zusammenhang mit der verabreichung von cv-ereignisse begünstigenden wirkstoffen

  2006cites this paper
• Beneficial effects of fraloxifene and atorvastatin on serum lipids

  2005cites this paper
• Evidence of improved serum fatty acid profile of postmenopausal women receiving atorvastatin and raloxifene

  2005cites this paper